{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:22:48Z","timestamp":1794072168044,"version":"4.8.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":69,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001773","name":"University of New South Wales","doi-asserted-by":"publisher","award":["Warwick L Morison Professorship in Dermatology"],"award-info":[{"award-number":["Warwick L Morison Professorship in Dermatology"]}],"id":[{"id":"10.13039\/501100001773","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Xeroderma Pigmentosum (XP), is a rare genetic condition characterised by extreme sensitivity to ultra violet (UV) radiation, conferring a 2,000- to 10,000-fold increased risk of developing melanoma and non-melanoma skin cancers. Families affected by XP face intense emotional strain, ongoing medical surveillance and intervention, and stringent lifelong adaptations to minimise UV exposure. Despite these challenges, little is known about the psychosocial burden experienced by children with XP and their immediate family members. This study explored the lived experiences and support needs, both medical and psychosocial, of families caring for a child with XP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>We conducted qualitative semi-structured interviews, in person or via Zoom, with parents and children affected by XP, examining diagnostic experiences, psychosocial impacts, care preferences, and informational needs. The interview guide was developed by a multidisciplinary expert panel. Eligible participants included parents of children with XP, and patients or siblings aged 5\u201318 years without intellectual disability. Participants were recruited via the Australian Paediatric XP Support Group, representing the full known XP cohort in Australia. Of the seven identified families, five contributed at least one parent participant. Among eight identified children, four were ineligible, and one was not enrolled. Interviews were audio-recorded, transcribed verbatim, and analysed using inductive, line-by-line coding in NVivo Pro. Descriptive statistics summarised participant demographics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eight parents (63% female, mean age 45 years) and three children (67% female, mean age 10 years) participated. Four themes emerged: (1) a prolonged and distressing diagnostic journey, often marked by misdiagnosis and uncertainty; (2) strong preferences for integrated, multidisciplinary care to reduce fragmentation; (3) significant psychosocial impacts, including isolation, anxiety-driven vigilance, and challenges adapting to absolute UV-protective routines; and (4) substantial unmet information needs at diagnosis, leaving families feeling overwhelmed and underprepared.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Families affected by XP experience significant and enduring psychosocial burden. Findings highlight the urgent need for coordinated, interdisciplinary support that extends beyond medical care. This study contributes to the growing call within the rare disease community for integrated care models that centre patient and family wellbeing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04410-6","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T17:17:51Z","timestamp":1780679871000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Living with Xeroderma Pigmentosum: a qualitative study of the psychosocial challenges experienced by families of children with a rare skin disorder"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2604-9975","authenticated-orcid":false,"given":"Jordana","family":"McLoone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyra","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Tucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoinette","family":"Anazodo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rtshiladze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda K.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"issue":"2","key":"4410_CR1","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/S1357-4310(98)01394-X","volume":"5","author":"H van Steeg","year":"1999","unstructured":"van Steeg H, Kraemer KH. Xeroderma pigmentosum and the role of UV-induced DNA damage in skin cancer. Mol Med Today. 1999;5(2):86\u201394.","journal-title":"Mol Med Today"},{"issue":"2","key":"4410_CR2","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1001\/archderm.1987.01660260111026","volume":"123","author":"KH Kraemer","year":"1987","unstructured":"Kraemer KH, Lee MM, Scotto J. Xeroderma pigmentosum: cutaneous, ocular, and neurologic abnormalities in 830 published cases. Arch Dermatol. 1987;123(2):241\u201350.","journal-title":"Arch Dermatol"},{"issue":"3","key":"4410_CR3","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1136\/jmg.2010.083022","volume":"48","author":"PT Bradford","year":"2011","unstructured":"Bradford PT, Goldstein AM, Tamura D, Khan SG, Ueda T, Boyle J, et al. Cancer and neurologic degeneration in xeroderma pigmentosum: long term follow-up characterises the role of DNA repair. J Med Genet. 2011;48(3):168\u201376.","journal-title":"J Med Genet"},{"issue":"12","key":"4410_CR4","doi-asserted-by":"publisher","first-page":"5044","DOI":"10.1093\/brain\/awad266","volume":"146","author":"H Garcia-Moreno","year":"2023","unstructured":"Garcia-Moreno H, Langbehn DR, Abiona A, Garrood I, Fleszar Z, Manes MA, et al. Neurological disease in xeroderma pigmentosum: prospective cohort study of its features and progression. Brain. 2023;146(12):5044\u201359.","journal-title":"Brain"},{"issue":"10","key":"4410_CR5","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1111\/1346-8138.13907","volume":"44","author":"S Moriwaki","year":"2017","unstructured":"Moriwaki S, Kanda F, Hayashi M, Yamashita D, Sakai Y, Nishigori C, et al. Xeroderma pigmentosum clinical practice guidelines. J Dermatol. 2017;44(10):1087\u201396.","journal-title":"J Dermatol"},{"key":"4410_CR6","unstructured":"Lucero R, Horowitz D, Xeroderma Pigmentosum. StatPearls. StatPearls Publishing LLC. Treasure Island, FL, USA; 2020."},{"key":"4410_CR7","volume-title":"Life Expectancy of Xeroderma Pigmentosum Patients: Evidence from a UK Study","year":"2025","unstructured":"Paolino A, Keogh R, Langan SM, Lehmann AR, Garrood I, Fassihi H, editors. Life Expectancy of Xeroderma Pigmentosum Patients: Evidence from a UK Study. WILEY 111 RIVER ST, HOBOKEN 07030\u2009\u2013\u20095774, NJ USA: JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT; 2025."},{"issue":"1","key":"4410_CR8","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1186\/1471-2407-13-372","volume":"13","author":"MJ Sneyd","year":"2013","unstructured":"Sneyd MJ, Cox B. A comparison of trends in melanoma mortality in New Zealand and Australia: the two countries with the highest melanoma incidence and mortality in the world. BMC Cancer. 2013;13(1):372.","journal-title":"BMC Cancer"},{"issue":"5","key":"4410_CR9","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","volume":"158","author":"M Arnold","year":"2022","unstructured":"Arnold M, Singh D, Laversanne M, Vignat J, Vaccarella S, Meheus F, et al. Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040. JAMA Dermatol. 2022;158(5):495\u2013503.","journal-title":"JAMA Dermatol"},{"key":"4410_CR10","doi-asserted-by":"crossref","unstructured":"Laouali S, Adam ND, Issaka H, Ma\u00efmouna OM, Sani LIM, Doulla M, et al. Xeroderma pigmentosum: twelve cases at the National Hospital of Niamey, Niger. Our Dermatology Online\/Nasza Dermatologia Online. 2023;14(1).","DOI":"10.7241\/ourd.20231.11"},{"issue":"11","key":"4410_CR11","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1136\/jmedgenet-2021-108323","volume":"59","author":"R Sarkany","year":"2022","unstructured":"Sarkany R, Norton S, Canfield M, Morgan M, Foster L, Sainsbury K, et al. Identifying the psychosocial predictors of ultraviolet exposure to the face in patients with xeroderma pigmentosum: a study of the behavioural factors affecting clinical outcomes in this genetic disease. J Med Genet. 2022;59(11):1095\u2013103.","journal-title":"J Med Genet"},{"key":"4410_CR12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.33590\/emjdermatol\/10311902","volume":"1","author":"M Sethi","year":"2013","unstructured":"Sethi M, Lehmann AR, Fassihi H. Xeroderma pigmentosum: a multidisciplinary approach. EMJ Dermatol. 2013;1:54\u201363.","journal-title":"EMJ Dermatol"},{"issue":"14","key":"4410_CR13","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1177\/1359105317714643","volume":"24","author":"R Anderson","year":"2019","unstructured":"Anderson R, Walburn J, Morgan M. Experiences of stigma over the lifetime of people with xeroderma pigmentosum: A qualitative interview study in the United Kingdom. J Health Psychol. 2019;24(14):2031\u201341.","journal-title":"J Health Psychol"},{"issue":"2","key":"4410_CR14","doi-asserted-by":"publisher","first-page":"e024445","DOI":"10.1136\/bmjopen-2018-024445","volume":"9","author":"M Morgan","year":"2019","unstructured":"Morgan M, Anderson R, Walburn J, Weinman J, Sarkany R. The influence of perceived medical risks and psychosocial concerns on photoprotection behaviours among adults with xeroderma pigmentosum: a qualitative interview study in the UK. BMJ open. 2019;9(2):e024445.","journal-title":"BMJ open"},{"key":"4410_CR15","unstructured":"Lumivero. NVivo (Version 12). 2017. https:\/\/www.lumivero.com."},{"key":"4410_CR16","unstructured":"Miles MB. Qualitative data analysis: an expanded sourcebook. Thousand Oaks. 1994."},{"issue":"1","key":"4410_CR17","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13023-017-0622-4","volume":"12","author":"Y Zurynski","year":"2017","unstructured":"Zurynski Y, Deverell M, Dalkeith T, Johnson S, Christodoulou J, Leonard H, et al. Australian children living with rare diseases: experiences of diagnosis and perceived consequences of diagnostic delays. Orphanet J Rare Dis. 2017;12(1):68.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"4410_CR18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13023-022-02190-3","volume":"17","author":"H Walton","year":"2022","unstructured":"Walton H, Simpson A, Ramsay AIG, Hunter A, Jones J, Ng PL, et al. Development of models of care coordination for rare conditions: a qualitative study. Orphanet J Rare Dis. 2022;17(1):49.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"4410_CR19","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1080\/08870446.2022.2072843","volume":"39","author":"KH Marshall","year":"2024","unstructured":"Marshall KH, Pincus HA, Tesson S, Lingam R, Woolfenden SR, Kasparian NA. Integrated psychological care in pediatric hospital settings for children with complex chronic illness and their families: a systematic review. Psychol Health. 2024;39(4):452\u201378.","journal-title":"Psychol Health"},{"key":"4410_CR20","doi-asserted-by":"crossref","unstructured":"Kenny T, Bogart K, Freedman A, Garthwaite C, Henley SM, Bolz-Johnson M, et al. The importance of psychological support for parents and caregivers of children with a rare disease at diagnosis. Rare Disease Orphan Drugs J. 2022;1(2):N\/A-N\/A","DOI":"10.20517\/rdodj.2022.04"},{"issue":"1","key":"4410_CR21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13023-022-02305-w","volume":"17","author":"RM Smits","year":"2022","unstructured":"Smits RM, Vissers E, Te Pas R, Roebbers N, Feitz WF, van Rooij IA, et al. Common needs in uncommon conditions: a qualitative study to explore the need for care in pediatric patients with rare diseases. Orphanet J Rare Dis. 2022;17(1):153.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"4410_CR22","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1186\/s12913-022-08060-9","volume":"22","author":"R Spencer-Tansley","year":"2022","unstructured":"Spencer-Tansley R, Meade N, Ali F, Simpson A, Hunter A. Mental health care for rare disease in the UK\u2013recommendations from a quantitative survey and multi-stakeholder workshop. BMC Health Serv Res. 2022;22(1):648.","journal-title":"BMC Health Serv Res"},{"key":"4410_CR23","doi-asserted-by":"publisher","first-page":"846965","DOI":"10.3389\/fonc.2022.846965","volume":"12","author":"NA Nasrallah","year":"2022","unstructured":"Nasrallah NA, Wiese BM, Sears CR. Xeroderma pigmentosum complementation group C (XPC): Emerging roles in non-dermatologic malignancies. Front Oncol. 2022;12:846965.","journal-title":"Front Oncol"},{"key":"4410_CR24","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/978-981-10-6722-8_8","volume-title":"DNA Repair Disorders","author":"H Fassihi","year":"2019","unstructured":"Fassihi H, Garrood I, Chandler N, Mohammed S, Lehmann AR, Sarkany R. Xeroderma Pigmentosum in the UK. In: Nishigori C, Sugasawa K, editors. DNA Repair Disorders. Singapore: Springer Singapore; 2019. pp. 99\u2013114."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04410-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04410-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04410-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T22:41:56Z","timestamp":1786574516000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04410-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4410"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04410-6","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"26 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study received approval from the Sydney Children\u2019s Hospital Network Human Research Ethics Committee (2023\/ETH\/02061) and all participants provided informed consent.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable; all data was deidentified.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no financial or competing interests to declare.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"277"}}